WO1996039126A2 - Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats - Google Patents

Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats Download PDF

Info

Publication number
WO1996039126A2
WO1996039126A2 PCT/US1996/008978 US9608978W WO9639126A2 WO 1996039126 A2 WO1996039126 A2 WO 1996039126A2 US 9608978 W US9608978 W US 9608978W WO 9639126 A2 WO9639126 A2 WO 9639126A2
Authority
WO
WIPO (PCT)
Prior art keywords
ranitidine
adsorbate
grams
magnesium trisilicate
added
Prior art date
Application number
PCT/US1996/008978
Other languages
English (en)
Other versions
WO1996039126A3 (fr
Inventor
Albert F. Sorg
Kirti H. Valia
Anthony B. Eoga
John Denick, Jr.
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to AU63787/96A priority Critical patent/AU6378796A/en
Publication of WO1996039126A2 publication Critical patent/WO1996039126A2/fr
Publication of WO1996039126A3 publication Critical patent/WO1996039126A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à un adsorbat de ranitidine, sur du trisilicate de magnésium, destiné à être administré par voie orale et qui n'a pas le goût amer et déplaisant associé à la ranitidine. La ranitidine incluse dans l'adsorbat se présente sous une forme stable et amorphe et est compatible avec des excipients pharmaceutiquement acceptables.
PCT/US1996/008978 1995-06-06 1996-06-05 Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats WO1996039126A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63787/96A AU6378796A (en) 1995-06-06 1996-06-05 Ranitidine salts on magnesium trisilicate as an adsorbate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46821695A 1995-06-06 1995-06-06
US08/468,216 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039126A2 true WO1996039126A2 (fr) 1996-12-12
WO1996039126A3 WO1996039126A3 (fr) 1997-01-30

Family

ID=23858888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008978 WO1996039126A2 (fr) 1995-06-06 1996-06-05 Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats

Country Status (2)

Country Link
AU (1) AU6378796A (fr)
WO (1) WO1996039126A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000238A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de produits d'adsorption de medicament amorphe
WO2005023225A1 (fr) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Adsorbat de cilostazol
EP1674078A3 (fr) * 2000-03-23 2007-07-25 Warner-Lambert Company LLC Films consommables par voie orale à dissolution rapide contenant une résine d'échange ionique comme agent de masquage du goût
EP2072042A1 (fr) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Ingrédient pharmaceutique actif sur support solide amorphe et avec solubilité améliorée
EP2238979A1 (fr) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636532A1 (fr) * 1988-09-20 1990-03-23 Glaxo Group Ltd Compositions pharmaceutiques
EP0526862A1 (fr) * 1991-08-06 1993-02-10 VECTORPHARMA INTERNATIONAL S.p.A. Compositions pharmaceutiques solides pour l'administration orale à séjour gastrique prolongé

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636532A1 (fr) * 1988-09-20 1990-03-23 Glaxo Group Ltd Compositions pharmaceutiques
EP0526862A1 (fr) * 1991-08-06 1993-02-10 VECTORPHARMA INTERNATIONAL S.p.A. Compositions pharmaceutiques solides pour l'administration orale à séjour gastrique prolongé

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674078A3 (fr) * 2000-03-23 2007-07-25 Warner-Lambert Company LLC Films consommables par voie orale à dissolution rapide contenant une résine d'échange ionique comme agent de masquage du goût
US7648712B2 (en) 2000-03-23 2010-01-19 Mcneil-Ppc, Inc. Fast dissolving orally consumable films containing a taste masking agent
EP2275091A1 (fr) * 2001-06-22 2011-01-19 Pfizer Products Inc. Compositions pharmaceutiques, comprenant des adsorbates d'un médicament amorphe
JP2005501820A (ja) * 2001-06-22 2005-01-20 ファイザー・プロダクツ・インク 非晶質薬剤の吸着物の医薬組成物
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
KR100768766B1 (ko) * 2001-06-22 2007-10-19 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
WO2003000238A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de produits d'adsorption de medicament amorphe
US8703199B2 (en) 2001-06-22 2014-04-22 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drug
US8389006B2 (en) 2001-06-22 2013-03-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drug
WO2005023225A1 (fr) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Adsorbat de cilostazol
EP2072042A1 (fr) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Ingrédient pharmaceutique actif sur support solide amorphe et avec solubilité améliorée
WO2009080698A1 (fr) * 2007-12-21 2009-07-02 Lek Pharmaceuticals D.D. Principe actif pharmaceutique sur un support solide, amorphe et à solubilité améliorée
EP2238979A1 (fr) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide

Also Published As

Publication number Publication date
AU6378796A (en) 1996-12-24
WO1996039126A3 (fr) 1997-01-30

Similar Documents

Publication Publication Date Title
US4647450A (en) Chewing gum compositions containing magnesium trisilicate absorbates
EP0239541B1 (fr) Adsorbats de médicaments avec des tensio-actifs et leur préparation
EP0239542B1 (fr) Adsorbats de médicaments avec des magnésium-aluminium silicates et leur préparation
EP0132472B1 (fr) Produits pharmaceutiques contenant un adsorbant à base d'un trisilicate de magnésium avec un agent pharmaceutique adsorbé là-dessus
EP0219458B1 (fr) Adsorbats de médicaments et leur préparation
US4761274A (en) Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
US4758424A (en) Medicament adsorbates of decongestants with complex magnesium aluminum silicate and their preparation
US4647459A (en) Confectionery compositions containing magnesium trisilicate adsorbates
US4717565A (en) Process for the preparation of medicament adsorbates
EP2560613B1 (fr) Composition à base de fexofénadine et sa méthode de préparation
US4632821A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of decongestants
US20030161888A1 (en) Pharmaceutical Composition
US4643898A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of nutritional supplements and laxatives
US4642231A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
US4650663A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
US4758425A (en) Medicament adsorbates of antiasthmatics with complex magnesium aluminum silicate and their preparation
WO1996039126A2 (fr) Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats
US4643892A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of analgesics
CN114096238A (zh) 一种阿可拉定的纳米胶束制剂及其制备方法和用途
US4649041A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
US5626878A (en) Reduction of electrostatic forces between magnesium trisilicate adsorbates
US4632822A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of antiasmatics
US4632823A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of appetite suppressants
US4647449A (en) Magnesium trisilicate suitable for preparation of medicament adsorbates of alkaloids
MXPA97004395A (en) Reduction of electrostatic forces between magne trisilicato absorbers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA